Corrigendum to: A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study)

Her2 Positive ◽

Oncology Group Study ◽

Phase Iii Study ◽

A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study)

Annals of Oncology ◽

10.1093/annonc/mdy272.349 ◽

2018 ◽

Vol 29 ◽

pp. viii118

Author(s):

A. Shimomura ◽

K. Tamura ◽

T. Mizutani ◽

T. Shibata ◽

F. Hara ◽

...

Keyword(s):

Breast Cancer ◽

Elderly Patients ◽

Phase Iii ◽

Advanced Stage ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Phase Iii Study ◽

Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208

Cancer Science ◽

10.1111/j.1349-7006.2007.00639.x ◽

2007 ◽

Vol 0 (0) ◽

pp. 071027181834001-???

Author(s):

Yutaka Tokuda ◽

Tomoo Tajima ◽

Masaru Narabayashi ◽

Kunihiko Takeyama ◽

Toru Watanabe ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Clinical Oncology ◽

High Dose Chemotherapy ◽

Phase Iii ◽

High Dose ◽

Oncology Group ◽

Oncology Group Study ◽

Randomized phase III study to evaluate the value of omission of prophylactic neck dissection for stage I/II tongue cancer: Japan Clinical Oncology Group study (JCOG1601, RESPOND)

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyy125 ◽

2018 ◽

Cited By ~ 2

Author(s):

Kiyo Tanaka ◽

Nobuhiro Hanai ◽

Junko Eba ◽

Junki Mizusawa ◽

Takahiro Asakage ◽

...

Keyword(s):

Neck Dissection ◽

Clinical Oncology ◽

Tongue Cancer ◽

Stage I ◽

Phase Iii ◽

Oncology Group ◽

Oncology Group Study ◽

Phase Iii Study ◽

Prophylactic Neck Dissection

Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)

Annals of Oncology ◽

10.1093/annonc/mdz394.005 ◽

2019 ◽

Vol 30 ◽

pp. v854-v855 ◽

Cited By ~ 3

Author(s):

M. Untch ◽

C.E. Geyer ◽

C. Huang ◽

S. Loibl ◽

N. Wolmark ◽

...

Keyword(s):

Breast Cancer ◽

Central Nervous System ◽

Nervous System ◽

Peripheral Neuropathy ◽

Phase Iii ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyv213 ◽

2016 ◽

Vol 46 (4) ◽

pp. 385-388 ◽

Cited By ~ 15

Author(s):

Junki Mizusawa ◽

Chigusa Morizane ◽

Takuji Okusaka ◽

Hiroshi Katayama ◽

Hiroshi Ishii ◽

...

Keyword(s):

Clinical Oncology ◽

Biliary Tract ◽

Biliary Tract Cancer ◽

Phase Iii ◽

Oncology Group ◽

Oncology Group Study ◽

Tract Cancer ◽

A randomized phase III study of cisplatin (CDDP), etoposide (ETOP) and irinotecan versus topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC): Japan Clinical Oncology Group study JCOG0605

10.1200/jco.2014.32.15_suppl.7504 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 7504-7504

Author(s):

Koichi Goto ◽

Yuichiro Ohe ◽

Takashi Seto ◽

Toshiaki Takahashi ◽

Kazuhiko Nakagawa ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Second Line ◽

Oncology Group ◽

Small Cell Lung ◽

Oncology Group Study ◽

Phase Iii Study ◽

Line Chemotherapy

Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine (cape) in patients with stage III colon cancer (CC): Results of Japan Clinical Oncology Group study (JCOG0910).

10.1200/jco.2015.33.15_suppl.3512 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 3512-3512 ◽

Cited By ~ 3

Author(s):

Tetsuya Hamaguchi ◽

Yasuhiro Shimada ◽

Junki Mizusawa ◽

Yusuke Kinugasa ◽

Yukihide Kanemitsu ◽

...

Keyword(s):

Colon Cancer ◽

Adjuvant Chemotherapy ◽

Clinical Oncology ◽

Phase Iii ◽

Stage Iii ◽

Oncology Group ◽

Oncology Group Study ◽

Stage Iii Colon Cancer ◽

Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213).

10.1200/jco.2015.33.15_suppl.tps4143 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS4143-TPS4143 ◽

Cited By ~ 3

Author(s):

Chigusa Morizane ◽

Nozomu Machida ◽

Yoshitaka Honma ◽

Takuji Okusaka ◽

Narikazu Boku ◽

...

Keyword(s):

Clinical Oncology ◽

Neuroendocrine Carcinoma ◽

Digestive System ◽

Phase Iii ◽

Oncology Group ◽

Oncology Group Study ◽

System A ◽

Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.

10.1200/jco.2016.34.15_suppl.593 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 593-593

Author(s):

Carlos H. Barrios ◽

David Cella ◽

Miguel Martin ◽

Wolfgang Eiermann ◽

Howard A. Burris ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Patient Reported Outcomes ◽

Advanced Breast ◽

Phase Iii ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Patient Reported ◽

0154 TEACH: Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with HER2-positive breast cancer

The Breast ◽

10.1016/s0960-9776(09)70185-7 ◽

2009 ◽

Vol 18 ◽

pp. S58 ◽

Cited By ~ 1

Author(s):

B. Moy ◽

J.D. Maltzman ◽

E. Rappold ◽

L. Nicolodi ◽

L.S. Williams ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Phase Iii ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Phase Iii Study ◽